GlassScriptPhysician profile
Aakash Bhargava
NPI 1689170466
$7,878.27
in general payments reported to CMS, 2019-2025
39 companies · $3,144 in 2025
The $3,144 reported for 2025 was more than what 81% of Pain Medicine (Psychiatry & Neurology) providers received nationally (typical 2025 total: $405).
See the full distribution for Pain Medicine (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $90.62 · 2023: $1,836 · 2024: $2,807 · 2025: $3,144.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,788.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,787.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,735.80 | 2023-2025 | Ubrelvy, Qulipta, Botox |
| Pfizer INC. | $1,154.97 | 2023-2025 | |
| Lundbeck LLC | $697.83 | 2023-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $413.20 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Ucb, INC. | $335.82 | 2023-2025 | Rystiggo, Briviact, Fintepla |
| Eisai INC. | $235.04 | 2023-2025 | |
| Alexion Pharmaceuticals, INC. | $209.10 | 2023-2025 | Ultomiris |
| Octapharma USA, INC. | $190.13 | 2024-2025 | Panzyga |
| Genentech USA, INC. | $172.06 | 2023-2025 | Ocrevus, Ocrevus Zunovo |
| Axsome Therapeutics, INC. | $163.87 | 2025 | Symbravo |
| Lilly USA, LLC | $148.07 | 2024-2025 | Kisunla, Amyvid |
| Biogen, INC. | $128.00 | 2023-2025 | Tysabri, Vumerity, Avonex |
| Takeda Pharmaceuticals U.S.A., INC. | $115.65 | 2024-2025 | Hyqvia |
| Scilex Pharmaceuticals INC. | $104.10 | 2024-2025 | |
| Argenx US, INC. | $99.55 | 2024-2025 | Vyvgart Hytrulo |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $88.38 | 2024-2025 | Acthar |
| Genzyme Corporation | $76.88 | 2024-2025 | |
| Kyowa Kirin, INC. | $73.64 | 2023-2024 | Nourianz |
| Tanabe Pharma America, INC. | $73.33 | 2023-2025 | Radicava |
| Amgen INC. | $64.32 | 2023-2025 | Uplizna, Aimovig |
| Otsuka America Pharmaceutical, INC. | $58.44 | 2023-2024 | Nuedexta |
| Ge Healthcare | $57.42 | 2024-2025 | |
| Impel Pharmaceuticals INC. | $56.39 | 2023 | Trudhesa |
| Grifols USA, LLC | $54.91 | 2024-2025 | Gamunex-C |
| Amneal Pharmaceuticals LLC | $40.09 | 2023 | Lyvispah |
| Alnylam Pharmaceuticals INC. | $35.96 | 2023 | Onpattro |
| Life Molecular Imaging LTD | $35.45 | 2025 | Neuraceq |
| Csl Behring | $33.64 | 2025 | Hizentra |
| Sk Life Science, INC. | $28.19 | 2024 | |
| Janssen Biotech, INC. | $24.66 | 2025 | |
| Averitas Pharma INC. | $23.60 | 2025 | Qutenza |
| Neurocrine Biosciences, INC. | $23.40 | 2025 | |
| Tg Therapeutics, INC. | $22.48 | 2023 | |
| Amylyx Pharmaceuticals, INC. | $18.98 | 2023 | Relyvrio |
| Tonix Medicines, INC. | $18.89 | 2025 | Zembrace Symtouch |
| Emd Serono, INC. | $18.14 | 2025 | |
| Cycle Pharmaceuticals INC | $17.38 | 2025 | Tascenso Odt |
| Kedrion Biopharma, INC. | $17.24 | 2024 | Rhogam Ultra-Filtered Plus, Gammaked, Albuked |
| Astrazeneca Pharmaceuticals LP | $13.27 | 2024 | Wainua |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aakash Bhargava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.